Lyell Immunopharma, Inc.
corporate_fare Company Profile
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for LYEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for LYEL spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- Lyell 10-Q: Q3 Net Loss Widens to $45.5M; $194M Cash Plus $80M Placement
- Q3 Loss Widens to $45.5M as Lyell Burns Cash Ahead of 2027 Pivotal Data
- Lyell Prices $80M Private Placement at $10.77/Share, 7.43M Shares
- $80M Private Placement Funds Ronde-Cel Push Toward BLA Filing
- Ronde-Cel Shows 77% Complete Response Rate in 3L+ Lymphoma Ahead of ASH
Financial Snapshot
Short Interest & Short Volume
10.43 days to coverFINRA reported short interest of 1,409,625 shares in LYEL as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 10.4 days to cover at its recent average daily volume. On November 20, 2026, 70.9% of LYEL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LYEL, detected from its recent SEC filings.
Resale Registration for Placement Shares · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →